Skip to main content
SYNAIRGEN PLC logo

SYNAIRGEN PLC — Investor Relations & Filings

Ticker · SNG ISIN · GB00B0381Z20 LEI · 213800IMMTOPPDF8HD24 IL Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2022-04-06 Major Shareholding Noti…
Country GB United Kingdom
Listing IL SNG

About SYNAIRGEN PLC

https://www.synairgen.com/

Synairgen PLC is a clinical-stage biotechnology company focused on the discovery and development of treatments for severe respiratory diseases. The company's primary focus is its lead investigative candidate, SNG001, an inhaled formulation of interferon-beta (IFN-β). SNG001 is being developed as a potential host-directed, broad-spectrum antiviral therapy delivered directly to the lungs. This approach aims to treat hospitalized patients with severe viral lung infections caused by a range of pathogens, including influenza, RSV, and coronaviruses.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is clearly identified by the 'RNS Number' header and contains the standard formatting for a regulatory notification disseminated via RNS (the news service of the London Stock Exchange). Specifically, the form title is 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is specific enough to warrant the MRQ classification over the general RNS fallback.
2022-04-06 English
Synairgen to present at ATS 2022
Regulatory Filings Classification · 99% confidence The document is identified by the RNS Number header and the presence of 'RNS Number : 2313H' and the closing statement referencing 'Reach' as a non-regulatory news service of the London Stock Exchange. The content primarily announces that further analysis of Phase 3 trial data will be presented at an upcoming conference (ATS 2022) and mentions that the full analysis will be submitted for peer-reviewed publication. It also announces the date for the FY 2021 financial results release. Since this document is an announcement about future presentations and the release of results, rather than the results themselves (like an ER or IR), and it is distributed via the RNS/Reach system, it fits best under the general Regulatory Filings category (RNS) as a specific announcement that doesn't map to a more precise category like ER, IR, or DIV. It is not a Report Publication Announcement (RPA) because it is announcing the *content* of the presentation/analysis, not just the publication of a formal report attached to this filing.
2022-04-05 English
Synairgen Provides Update on ACTIV-2 Trial
Regulatory Filings Classification · 100% confidence The document is identified by the 'RNS Number' header and contains a date (17 March 2022) and company information, typical of a regulatory news service announcement. The content discusses an update on a clinical trial (ACTIV-2) involving the company's drug (SNG001) and mentions that the announcement contains 'inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')'. This structure strongly indicates a general regulatory announcement released via the London Stock Exchange's RNS system. Since it is not a full financial report (10-K, IR), a specific legal update (LTR), or a management change (MANG), the most appropriate general category for a time-sensitive regulatory news release is 'Regulatory Filings' (RNS). The document is not merely announcing the publication of another report, but is the primary news release itself.
2022-03-17 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document explicitly starts with 'RNS Number' and contains information about a 'Second Price Monitoring Extension' related to trading on the London Stock Exchange. It concludes by stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This clearly identifies the document as a general regulatory announcement distributed via the RNS system, which corresponds to the 'Regulatory Filings' category.
2022-03-14 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1911 characters) and contains the header 'RNS Number : 7286E'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory filing category.
2022-03-14 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1928 characters) and contains the header 'RNS Number : 5589E'. It announces a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the FCA as a Primary Information Provider. This type of immediate, non-periodic regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or IR) is best classified as a general Regulatory Filing (RNS). It is not an announcement of a report (RPA), but a direct regulatory update.
2022-03-11 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.